DSOL — Drug Free Solution Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -41320% | ||
Financial Summary
| Year End 31st May | Unit | 2009 | 2010 | 2011 | 2012 | 2013 | 2014E | 2015E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Drug Free Solution, Inc., is into healthcare industry and home healthcare services. The Company is engaged in acquiring healthcare operations that focuses on home healthcare, developmental disabilities, hospice care, skilled nursing, residential rehabilitation, home and community-based services.
Directors
- Last Annual
- May 31st, 2013
- Last Interim
- February 28th, 2014
- Incorporated
- April 14th, 2011
- Public Since
- January 1st, 2012
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 373,848,345
- Address
- 531 Main St. # 670, EL SEGUNDO, 90245
- Web
- http://www.drugfreesolution.com/
- Phone
- +1 7024306148
- Auditors
- PKF O'Connor Davies
Similar to DSOL
4Cable TV International
Pink Sheets on Nasdaq
Abattis Bioceuticals
Pink Sheets on Nasdaq
Accelera Innovations
Pink Sheets on Nasdaq
Quantum Medical Transport
Pink Sheets on Nasdaq
Aesthetic Medical International Holdings
Pink Sheets on Nasdaq
FAQ
As of Today at 20:19 UTC, shares in Drug Free Solution are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Drug Free Solution last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Drug Free Solution share price has underperformed the S&P500 Index by -6.57% over the past year.
There is no consensus recommendation for this security.
Find out moreDrug Free Solution does not currently pay a dividend.
Drug Free Solution does not currently pay a dividend.
Drug Free Solution does not currently pay a dividend.
To buy shares in Drug Free Solution you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Drug Free Solution had a market capitalisation of .
Here are the trading details for Drug Free Solution:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: DSOL
Based on an overall assessment of its quality, value and momentum Drug Free Solution is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Drug Free Solution. Over the past six months, its share price has outperformed the S&P500 Index by +3.51%.
As of the last closing price of $0.00, shares in Drug Free Solution were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Drug Free Solution PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Drug Free Solution's management team is headed by:
- Konstantin Kupert - PRE
- Genie O'Malley - CEO